US FDA again extends comment deadline for generic user fee proposal
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has again extended the comment deadline for stakeholder feedback on its proposed user fee programme for generic drugs; comments will now be accepted until 1 August1.